Epilepsy, X-linked 1, with variable learning disabilities and behavior disorders
MONDO:0010339An epilepsy, X-linked, with or without impaired intellectual development and dysmorphic features characterized by epilepsy, learning difficulties, macrocephaly, and aggressive behavior. It has been described in males from a four-generation kindred. It is transmitted as an X-linked recessive trait and is likely to be caused by mutations in the gene encoding synapsin I (Xp11.3-q12).
Also known as: X-linked epilepsy-learning disabilities-behavior disorders syndrome, epilepsy, X-linked, with variable learning disabilities and behavior disorders, X-linked recessive, X-linked dominant, epilepsy, X-linked, with variable learning disabilities and behaviour disorders, X-linked recessive, X-linked dominant, epilepsy, X-linked, with variable learning disabilities and behavior disorders, epilepsy, X-linked, with variable learning disabilities and behaviour disorders
7 clinical trials for this condition and its sub-types, 0 tagged with Epilepsy, X-linked 1, with variable learning disabilities and behavior disorders itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Real-World study tracks Epidyolex's Long-Term impact on seizures
Disease control OngoingThis study follows 158 people in France who are prescribed Epidyolex (a cannabidiol-based medicine) for seizures as part of their normal care. Researchers will track how long people stay on the treatment, side effects, seizure frequency, and changes in daily functioning and quali…
Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New inhaler aims to stop prolonged seizures fast and safely
Symptom relief By invitation onlyThis study tests the long-term safety of an inhaled medication called Staccato alprazolam for people aged 12 and older who have prolonged seizures. About 300 participants will use the inhaler when a seizure starts to see if it stops the seizure quickly and without serious side ef…
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC